ProPhase Labs, Inc. Entity Listing, Par Value Per Share
ProPhase Labs, Inc. (PRPH) reported Entity Listing, Par Value Per Share of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Cover Page
dei:EntityListingParValuePerShare · last filed 2026-08-19
- ProPhase Labs, Inc. entity listing, par value per share for the quarter ending 2026-03-31 was $0.00.
- ProPhase Labs, Inc. entity listing, par value per share for fiscal 2024 was $0.00.
| Period end | Entity Listing, Par Value Per Share 3 month | Entity Listing, Par Value Per Share 6 month | Entity Listing, Par Value Per Share 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-19 | ||
| 2026-03-31 | $0.00 10-Q/A · filed 2026-07-09 | ||
| 2024-12-31 | $0.00 10-K/A · filed 2025-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |